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INTRODUCTION
Surgical procedures in patients with obstructive jaundice are associated with
significant morbidity and mortality 1. This is due, to a large extent, to the develop-
ment of postoperative complications such as sepsis, bleeding disorders and renal
failure24. Clinical and experimental studies have suggested several aetiological
factors for these complications including hypotension, impaired nutritional status,
impaired immune function and the presence of potential toxic substances in the
circulation such as bilirubin and bile acids1’5’6. However, in recent years, there has
been an increasing recognition of the role of circulating endotoxins in the develop-
ment of complications in obstructive jaundice4’7-9.
The focus of this review will be the proposed association between the presence of
systemic endotoxaemia in obstructive jaundice and the subsequent development of
systemic complications. The experimental and clinical evidence for the existence of
portal and systemic endotoxaemia in obstructive jaundice will be reviewed, fol-
lowed by an outline of the current theory on the origin and mechanisms of
development of endotoxaemia. The effects of endotoxaemia in jaundiced animals
and patients, and the mechanisms by which these may be produced, will then be
reviewed. The recognition of endotoxaemia as a possible cause of complications in
obstructive jaundice and other pathological situations has led to the development
of a variety of therapeutic strategies, including the use of anti-endotoxin agents,
and these will be discussed.
Is the Development of Endotoxaemia in Obstructive Jaundice a Definite
Pathological Entity?
Since the association between the presence of endotoxaemia and renal failure in
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obstructive jaundice was reported by Wardle and Wright in 1970, several animal
and clinical studies have been performed to detect endotoxin in the circulation in
obstructive jaundice7. The significance of the results of these studies obviously
depends on the accuracy and reproducibility of the method used for detection of
endotoxin.
In 1956, Bang reported that a lysate derived from blood cells (amoebocytes) of
the horseshoe crab (Limulus Polyphemus) clotted in the presence of minute
amounts of gram-negative bacterial endotoxin1. This Limulus amoebocyte lysate
(LAL) reaction has formed the basis for the Limulus assay used to detect serum
endotoxin. The LAL reaction involves the activation, by endotoxin, of a proen-
zyme in the Limulus lysate. This results in release of a clotting enzyme which reacts
with a protein, derived from sheep erythrocytes, resulting in the formation of a gel.
This is the basis of the standard Limulus assay which, therefore, provides a
qualitative detection of the presence of serum endotoxin11.
In 1978, Iwanga et al. reported that the activated LAL proenzyme (clotting
enzyme referred to in the standard assay) would cleave p-nitroaniline (pNA)
substrates and that this could be used as a quantitative assay for endotoxaemia12.
The principle of the quantitative assay is that the enzyme formed from the
proenzyme in the LAL, following activation by endotoxin, catalyses the splitting of
pNA from a chromogenic substrate. The release of pNA is directly proportional to
endotoxin concentration and is measured photometrically. The amount of enzyme
needed to split the chromogenic substrate is much less than the amount needed to
form a clot, as in the standard assay. The chromogenic assay is, therefore,
approximately 100 times more sensitive than the standard assay and is capable of
detecting endotoxin in concentrations as low as 10 pg/m113.
There are several problems with the Limulus reaction which have not been
solved by the development of the quantitative assay. These are related principally
to the presence of proteins in plasma (e.g. esterases, elastases, anti-thrombin III)
which influence and inhibit the reaction between endotoxin and the LAL315.
Several methods have been employed to inactivate or remove these but the
preferred technique is dilution and heat treatment3’58. In addition, endotoxin
may be denatured rapidly if blood is not kept at4C immediately after sampling and
problems with the assay often occur as a result of exogenous contamination with
endotoxin18’19. This, in addition to the natural variability of the LAL, means that
there is often a high batch variability and poor reproducibility of the assay18’19.
For these reasons, results of studies utilising the Limulus assay may be variable
and must always be interpreted with great care. The results of animal and clinical
studies reported to date are summarised in Table 1. The vast majority of studies
report a positive correlation between the presence of obstructive jaundice and the
development of significant portal and/or systemic endotoxaemia, but in two of the
animal studies, no significant portal or systemic endotoxaemia was detected. This is
noteworthy as in these studies the chromogenic assay was used and if the
development of endotoxaemia is a definite pathological entity, it is surprising that
neither significant portal nor systemic endotoxaemia was detected3,31. However,
despite these two contradictory reports, the majority of experimental data supports
the development of endotoxaemia and in many of the studies, a definite relation-
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Table 1 Summary of studies investigating the development of endotoxaemia in obstructive jaundice.
Significant portal and/or systemic endotoxaemia detected
Animal studies
Bailey 19768
Gouma et al. 19862.
Diamond et al. 199021.
Human studies
Wilkinson et al. 197422.
Wardle 197423.
Wilkinson et al. 19764.
Bailey 19768
Hunt et al. 19823.
Cahill 19839.
Ingoldby 198426.
Pain and Bailey 198627
Gawley et al. 198829.
Significant portal and systemic endotoxaemia NOT detected
Animal studies
Roughneen et al. 19883.
Greve et al. 199031.
Origin and Mechanism of Development of Endotoxaemia
The largest reservoir of gram-negative organisms in the body is the large bowel32.
This is, therefore, the largest potential site from which endotoxaemia may originate
but, theoretically, any infected focus or duct system in the body could act as a
source of endotoxaemia. While the large bowel is thought to be the most likely
source of endotoxaemia in obstructive jaundice, it should be remembered that a
significant proportion of jaundiced patients have infection in the biliary system
particularly if an invasive procedure has been performed. This may be another
potential source of endotoxin33.
It is postulated that, in patients with obstructive jaundice, there are two major
contributing factors in the development of endotoxaemia. Firstly, the absence of
bile salts in the gut results in an alteration of the bacterial flora and loss of the
emulsifying anti-endotoxin effect of bile salts results in a larger pool of endotoxin in
the lar e bo f r b 0 34 35 g we, 0 a sorption "nto the p rtal circulation’ Secondly, impair-
ment of hepatic_ Kupffer cell phagocytic function in obstructive jaundice allows
spillover of endotoxin into the systemic circulation with subsequent development of
systemic complications (Figure 1)
36-38,39
This hypothesis provides a simple model for the understanding of the develop-
ment of endotoxaemia in biliary obstruction, but the situation is likely to be more
complex. Other factors affecting enteric endotoxin production and portal absorp-
tion may be important. Anti-endotoxin secretory IgA produced from the liver,
which contributes significantly to gut immunity, is reduced in obstructive
jaundice4, and other non-specific factors such as changes in mucosal permeability,
effects of hyperbilirubinaemia and changes in mucosal blood flow may all affect the84 T. DIAMOND AND B. J. ROWLANDS
integrity of the bowel wall as a mechanical and physiological barrier to the passage
of bacteria and toxins into the portal circulation41’42.
This phenomenon of passage of bacteria or bacterial toxins from the gut lumen is
known as bacterial translocation and has been shown to occur experimentally under
a variety of circumstances such as mucosal damage, bowel ischaemia, trauma,
SYSTEMIC ENDOTOXAEMIA
Impaired Kupffer
Cell Activity
PORTAL ENDOTOXAEMIA
Extra Hepatic
Biliary Obstruction
Figure 1 Proposed origin and mechanism of development of endotoxaemia in obstructive jaundice.ENDOTOXAEMIA IN OBSTRUCTIVE JAUNDICE 85
burns, systemic administration of endotoxin and obstructive jaundice43-45. It seems
from some of these studies that circulating endotoxin itself is one of the factors
which can alter gut permeability and in obstructive jaundice, lack of bile flow and
other factors predispose to portal absorption of endotoxin and impaired reticuloen-
dothelial function allows systemic endotoxaemia to develop. This further impairs
the gut barrier to portal absorption of endotoxin and a vicious positive feedback
circle is entered which ultimately leads to the development of overwhelming
systemic endotoxaemia.
Effects of Endotoxaemia in Obstructive Jaundice
Renal failure
Approximately 65% of patients with obstructive jaundice develop impaired renal
function following surgery and in 10-20% renal failure Occurs6’8’9’46’47. Proposed
aetiological factors, based on animal and human experiments include hypovolae-
mia, hypotension and possible toxic agents such as bilirubin and bile salts but, in
recent years, studies have concentrated on the role of endotoxaemia as a causative
factor69. There is a strong correlation in human and animal studies between the
presence of endotoxins in the systemic circulation and renal impairment4’79’26.
Furthermore, renal impairment is rare in the absence of endotoxaemia4’8.
Endotoxin causes a marked increase in renal vascular resistance, possibly as a
result of renal fibrin deposition due to intravascular coagulation47. Affected kidneys
show glomerular and peritubular fibrin deposition, leading to acute tubular necro-
sis. These changes are similar to those seen in the Schwartzmann reaction produced
by repeated injections of endotoxin in animals and this is a proposed mechanism of
acute renal failure in obstructive jaundice7.
Sepsis
Infective complications such as wound infection, septicaemia and peritonitis occur
more frequently in jaundiced patients and contribute largely to the reported high
morbidity and mortality2’5’48’49. Impairment of immune function has been suggested
as a possible cause. This is based on the demonstration in several animal and
human studies of impairment of both reticuloendothelial function and cellular
immune function37,5. Thus, endotoxaemia may have a causative role in the
development of infective complications as endotoxin is known to alter immune
function32,51.
Wound healing
Impaired wound healing, as measured by bursting strength, has been demonstrated
in animals with obstructive jaundice53’54. In jaundiced patients, incisional herniae
have been shown to occur in approximately 10% and wound dehiscence in
approximately 3% of patients48,52.
The exact cause of this apparent impairment of wound healing in obstructive
jaundice has not been fully elucidated. The presence of malignancy and poor
52 55 nutritional status are thought to be significant factors It has also been suggested
that impaired wound healing may be associated with endotoxaemia as improved
wound healing has been demonstrated in jaundiced rats treated with oral bile salts,
a therapy said to prevent endotoxaemiaTM.86 T. DIAMOND AND B. J. ROWLANDS
Coagulation disorders
Postoperative haemorrhage is a significant complication following surgery in
jaundiced patients5’49’76. This was initially thought to be due to vitamin K deficiency
as a result of malabsorption of the fat soluble vitamins57. However, despite normal
coagulation, some patients develop postoperative gastrointestinal haemorrhage
due to acute gastric erosions58. Animal studies demonstrate that endotoxin admi-
nistration induces similar gastric lesions and it has been suggested that these are
caused by endotoxaemia in patients59’6.
Disseminated intravascular coagulation (DIC)has been reported in obstructive
jaundice, particularly in association with biliary tract infection and
endotoxaemiaTM. Wardle reported decreased fibrinolytic activity in jaundiced
patients but Hunt et al. reported the presence, in serum, of increased fibrinogen
degradation products (FDP), associated with endotoxaemia and post operative
mortality3,23.
There are, therefore, several suggested explanations for the haemorrhagic
complications seen in jaundiced patients. Firstly, prolongation of the prothrombin
time caused by malabsorption of vitamin K and impaired ability of the liver to
manufacture prothrombin. Secondly, an increased fibrinolytic activity leading to
ineffective coagulation and thirdly, the presence of gastric erosions. The latter two
phenomena are thought to be due to endotoxaemia.
Multiple system organ failure
The progressive deterioration of function in organ systems, either simultaneously
or sequentially, is known as organ failure6264. The syndrome of multiple system
organ failure (MSOF) occurs following failure of two or more major organ support
systems62. Failure of the respiratory, renal and cardiovascular systems is the most
frequently encountered combination but failure of other vital support functions
including the gastrointestinal, hepatic, coagulation and central nervous systems are
important components of the MSOF syndrome. Sepsis is the principal activating
factor in the development of MSOF but it is also thought that endotoxaemia is an
important aetiological factor63’64.
When the features of the multiple system organ failure syndrome are compared
to the complications in obstructive jaundice, there is a very strong similarity
between the two clinical situations. It seems possible, therefore, that organ failure
in obstructive jaundice and the multiple system organ failure syndrome are similar
entities. Not only are the two clinical situations relatively similar but similarities in
the origin of these also exist i.e. the presence of sepsis and endotoxaemia.
Mechanism of Endotoxin-induced Complications
How does the presence of systemic endotoxaemia produce failure of individual
organs and organ systems? The effects of endotoxaemia on the host are so
widespread that it seems unlikely that they could all be produced by endotoxin
directly. It is thought that endotoxin acts as the afferent side or activating agent of
an inflammatory response which leads ultimately to impairment of organ function.
Other activating agents of this inflammatory cascade are bacterial infection and
severe tissue injury with necrosis. This concept of activation, mediation and end
organ effects has been popularised by Cerra to help understand how an insult such
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multiple system organ failure syndrome and is also a very useful model for
explaining the consequences of endotoxaemia in obstructive jaundice65.
Biological mediators
Activation of the inflammatory response leads to the release of a vast array of
inflammatory mediators. These may be released from endothelial cells but the
majority are released from leucocytes such as neutrophils and particularly from
cells of the monocyte-macrophage system. All of these mediators are part of
normal host defence but may become overstimulated and produce organ dysfunc-
tion through complex interactions between cells and mediators. Examples include
oxygen radicals, serotonin, histamine, fibronectin and more recently discovered
cytokines such as leucotrienes, interleukins, eicosanoids and tumour necrosis factor
(TNF)66,67.
The eicosanoids are a group of products which are formed from arachidonic acid.
Metabolism via the cyclooxygenase pathway produces the prostaglandins and these
are thought to be important as mediators of the effects of endotoxin in obstructive
jaundice. Significant elevation of plasma thromboxane and inhibition of 6-0xo-
prostaglandin Fl-alpha has been demonstrated following endotoxin administration
and bile duct ligation in rats47’68.
End organ effects
The mechanisms by which the biological mediators engage the efferent or effector
side of the inflammatory cascade and produce impairment of organ function are
referred to as end-organ effects. These include changes in the microcirculation, cell
membrane permeability, oxygen delivery, cellular metabolism, vascular permeabi-
lity and activation of the coagulation system with resultant microembolisation51.
These changes occurring at a cellular and microvascular level ultimately produce
alterations in organ function such as impaired glomerular filtration in the kidney
leading to renal failure or impaired oxygen transport in the lungs leading to
respiratory failure and the adult respiratory distress syndrome4’5’7’66.
ANTI-ENDOTOXIN THERAPY IN OBSTRUCTIVE JAUNDICE
Biliary Drainage
Preoperative, percutaneous external biliary decompression was introduced to
prepare patients for definitive surgery for obstructive jaundice but prospective
clinical trials failed to show any significant improvement in morbidity or mortality
following the use of this technique6972. A study in rats demonstrated that following
relief of biliary obstruction by internal drainage, endotoxaemia was reduced but
following external drainage, endotoxaemia was unaffected2. Thus, it was proposed
that failure of external drainage in jaundiced patients was due to persistence of
endotoxaemia, as a result of failure of return of bile to the gastrointestinal tract2.
However, using a technique for sterile, uncomplicated external biliary drainage
in the rat, it has been demonstrated that endotoxaemia was reversed by both
21 73 internal and external biliary drainage It has, therefore, been suggested that
return of bile to the gut may not be as important in the prevention of endotoxae-
mia, as previously supposed, and failure of external drainage in animal and patient88 T. DIAMOND AND B. J. ROWLANDS
studies may have been due to local complications associated with the drainage
cannula, such as bleeding, bile leakage and the development of local and systemic
infection21. The importance of these complications has also been highlighted in
several clinical studies33’71’79.
In patients, it should be possible to avoid some of the complications associated
with percutaneous liver puncture and drainage by performing endoscopic internal
biliary drainage. Improvement in complication rates and mortality following
pancreatic resection have been demonstrated using this technique28. However, no
studies on the efficacy of endoscopic biliary decompression in reversing endotoxae-
mia have been reported.
Large bowel irrigation
As the large bowel is thought to be the site of origin of endotoxin in obstructive
jaundice, it has been suggested that irrigation and lavage to reduce bacterial
numbers could be beneficialTM. This has been shown to be beneficial in prevention of
endotoxaemia in patients with inflammatory bowel disease but in jaundiced
patients studied by Hunt, bowel preparation did not produce any significant
benefit75,76.
Bile salts
Bile salts have antibacterial effects and a direct detergent effect on the lipopolysac-
charide endotoxin molecule and are thought to play an important role in the
defence against bacterial endotoxins77’78. The theoretical basis for their oral admi-
nistration in obstructive jaundice is that they replace the normal protective anti-
endotoxin effect of bile which is lost in complete biliary obstruction and, therefore,
help reduce the endotoxin pool in the large bowel.
The potential therapeutic effect of oral bile salts may be due to a direct anti-
endotoxin effect as it has been reported that biliary diversion does not alter
gastrointestinal flora and that there is no alteration in the gut flora of jaundiced
patients9’78’79. However, in a recent study in mice, in which caecal bacterial
populations were quantified, the levels of gram-negative enteric bacilli were 100-
fold higher in bile duct ligated animals compared to sham operated and control
groups44. The potential therapeutic effect of bile salts may, therefore, be due to a
combination of an anti-bacterial effect and a direct anti-endotoxin effect.
Koscar et al. showed that endotoxin absorption was increased in rats in the
absence of bile salts and oral administration of bile salts has shown to significantly
reduce mortality following endotoxin administration in jaundiced rats3’34.
In patients, preoperative oral bile salt administration has been reported to
prevent systemic endotoxaemia and protect postoperative renal function9’79.
However, a prospective, randomised clinical trial of oral ursodeoxycholic acid in
obstructive jaundice showed no significant benefit in terms of systemic endotoxae-
mia, renal function or postoperative outcome8. In the study by Cahill deoxycholic
acid was used and in the study by Evans et al. taurocholate was used9’79. Gawley et
al. reported that sodium deoxycholate reduced endotoxaemia in jaundiced patients
but in contrast to the previous study by Cahill an impaired renal function was
actually found in the bile salt treated patients9’29.
Recent studies have shown that ursodeoxycholic acid is much less potent as an
anti-endotoxin agent than deoxycholic acid and this was proposed as an explanation
for the poor results of the clinical trial carried out by Thompson et al. 9’8’8.ENDOTOXAEMIA IN OBSTRUCTIVE JAUNDICE 89
However, this does not explain the impaired renal function observed in the group
of patients treated with sodium deoxycholate by Gawley et a129.
The results of studies of oral bile salts, endotoxaemia and renal function in
patients with obstructive jaundice are conflicting and no definitive conclusion on
the efficacy of their use can be made. One important aspect which is not addressed
in any of these papers is the fact that, in the gastrointestinal tract, the vast majority
of intraluminal bile salts are absorbed in the terminal ileum (enterohepatic
circulation). For example, less than 5% of deoxycholate actually enters the colon82.
If the colon acts as a reservoir of bacteria and endotoxins, it seems unlikely that
such a small percentage of bile salts entering the colon could have an important
protective effect in the normal individual. In addition, in the patient with obstruc-
tive jaundice, administered bile salts may be absorbed in the terminal ileum and not
reach the colon- the site which is proposed to be the major source of endotoxin1’8.
This factor, in addition to the conflicting results of the studies mentioned above,
would seem to be the major criticism of the theoretical basis for advocating
preoperative bile salt administration in patients with obstructive jaundice.
Lactulose
Oral lactulose has been shown to have anti-endotoxin effects in animals and is used
in the treatment of patients with endotoxaemia secondary to liver disease4’8385.
Lactulose reduces endotoxin related mortality and improves survival in bile duct
ligated rats27’87. It has also been reported to reduce endotoxaemia and protect renal
function in jaundiced patients and preoperative oral laciulose therapy is now
recommended in patients with obstructive jaundice27.
Prostaglandin manipulation
Pharmacological manipulation of the thromboxane/prostacyclin ratio by pretreat-
ment with indomethacin, dazoxiben and prostacyclin improves renal fibrin deposi-
tion and survival and prevents the increase in urinary prostaglandin excretion
usually seen following bile duct ligation47’68. However, no follow-up study has been
performed in patients.
Polymyxin
The cationic polypeptide antibiotic polymyxin B has anti-endotoxin properties88.
Ingoldby demonstrated improved survival following an endotoxin challenge in
jaundiced rats treated with polymyxin B but a follow-up study in jaundiced patients
failed to demonstrate any beneficial effect26’89.
Taurolidine
Taurolidine is an antimicrobial compound with an anti-endotoxin effect. It acts by a
chemical reaction, releasing methylol groups (CH2OH) which become available to
bind to and inactivate bacteria or endotoxin as taurolidine is metabolised through
tauroltam to taurinamide and eventually to taurine9. Taurolidine has been shown
to improve survival following endotoxin administration in jaundiced rats and to
reduce endotoxaemia in experimental biliary obstruction but, to date, there are no
reports of clinical trials of its efficacy in patients with obstructive jaundice91’92.
Endotoxin antibodies
The continuing high mortality from gram-negative septicaemia and shock, despite90 T. DIAMOND AND B. J. ROWLANDS
the introduction of new and powerful antibiotics, has stimulated interest in the
concept of anti-endotoxin immunotherapy. Two different approaches have been
used to obtain antiserum with a wide range of anti-endotoxin activity. Antibodies
have been developed against the oligosaccharide side chain of endotoxin
(anti-LPS)25. The problem with these is that the 0 side chain is "strain specific" and
antibody developed against endotoxin from one strain of bacteria would not be
effective against that from another.
Because the toxic effects of endotoxin are associated with the core glycolipid
region, in which there is little strain variation, development of antibodies against
the core glycolipid region protects against a wide variety of gram-negative bacteria
and endotoxins93’94. These antibodies are raised using so called "rough" mutant
strains of gram-negative bacteria (e.g. Escherichia Coli J5 and Salmonella
Minnesota R595). This may represent a possible therapeutic strategy in patients
with obstructive jaundice but to date, no studies of the efficacy of anti-endotoxin
immunotherapy in preventing complications associated with endotoxaemia in
obstructive jaundice have been reported.
Antibiotics
Oral, non-absorbable antibiotics, such as neomycin, may decrease the colonic
bacterial population but this may be detrimental in that bacterial death may
actually increase the amount of free endotoxin available for portal absorption86.
Preoperative oral antibiotics are, therefore, not recommended as an anti-endotoxin
therapy in obstructive jaundice 1.
CONCLUSIONS
This review has focused on the proposed development of endotoxaemia in obstruc-
tive jaundice. The problems with the assay used to detect endotoxin and the
necessity for cautious interpretation of results is emphasised. Despite these reserva-
tions, the majority of animal and clinical studies, reported to date, support the
theory of development of significant portal and systemic endotoxaemia and subse-
quent systemic complications in obstructive jaundice. Several therapeutic strategies
have been proposed but, so far, no single anti-endotoxin therapy has emerged as a
very significant breakthrough in the management of obstructive jaundice. Further
study of these, including prospective clinical trials employing single or multiple
strategies for the prevention of endotoxaemia, are required.
An additional requirement to further elucidate the mechanisms of the complica-
tions attributed to endotoxaemia, is a more specific and reproducible assay for the
detection of endotoxin. Modification of this assay to allow detection of endotoxin in
other body fluids, such as bile, would allow assessment of the significance of
infection in the biliary tree as a potential souce of endotoxaemia. Further investi-
gation of other possible therapeutic measures in obstructive jaundice, such as
biliary drainage, enhancement of immune function and pharmacological manipula-
tion of inflammatory mediators, is also indicated.
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